Corynebacterium diphtheriae is the bacterium responsible for diphtheria, which is quite an active infection. Our firm is leading the path on diphtheria vaccines and therapy thereby making use of modern research and advanced facilities to provide pharmaceutical companies globally with assets that are truly one of its kind.
Overview of Diphtheria
Diphtheria is an extremely serious and even fatal infectious disease brought about by the bacteria Corynebacterium diphtheriae. The infection does not always present the same symptoms, as in some, it can grossly escalate the mortality rate to almost 10 percent. To make matters worse, transmission is considered to be through contact, respiratory means, and even through foreign objects infected with the bacteria in the first place which highlights the severity of the disease especially in underdeveloped areas such as sub-Saharan Africa, South Asia and Indonesia.
Fig. 1 Schematic representation of diphtheria toxin. (Shafiee F., et al., 2019)
Vaccine Development for Diphtheria
The primary method of avoiding diphtheria utilizes diphtheria toxoids in the form of three initial doses. Usually, these are administered with the standard vaccinations of children which include vaccines against pertussis and tetanus. The initial dose has to be complemented with additional doses after a certain period to preserve immunity against the disease by continuing with the use diphtheria containing vaccines.
It is understandable appropriate measures are put in place to reach people who are not vaccinated or have only been partially vaccinated hence the introduction of backward estimations. This ensures that those who could miss the series of vaccines or the boosting dosage are properly covered irrespective of their age so as to lessen the chances of occurrence the disease.
Therapeutics Development for Diphtheria
Diphtheria antitoxin is employed in the therapy of severe cases with a clinical diagnosis whenever it’s needed and it is obtained from the sera of animals that have been immunised against the diphtheria toxin to nullify the presence of free toxins in the body. In addition to those antibiotics: erythromycin, procaine penicillin G, rifampin or clindamycin are administered in order to destroy the C. diphtheria and to curtail further infectivity. Since antibiotics do not influence the already bound toxin, they are essential in curbing infection but do not reinstate the body.
We strive to improve, make new antitoxins and antibiotics while it is possible to minimize the development of resistance against their action and we wish to broaden the scope of diphtheria treatment. Please, click on the bottom link to find out more about how we help in developing therapies in one place.
Our Services
Diphtheria vaccine and therapy development is our forte, and with our seasoned professionals and academicians by our side, we have no issue in providing custom solutions. We consider ourselves lucky to assist numerous important clients with such a large array of services.
Disease Models
- Transgenic Mice Expressing the Diphtheria Toxin Receptor (DTR)
- Mouse Infection Models
- Guinea Pig Infection Models
- Others
Our company is constantly working on improving the diphtheria vaccine and cure, which enables us to pay closer attention to this and other infectious diseases. We ensure safety and efficiency during our clinical and preclinical research services which better the medicine development of the next generation diptheria medication. If our offers are of interest to you, we invite you to contact us for further details and for more precise pricing for the services you are looking for.
References
- Shafiee F., Marc G. Aucoin, and Ali Jahanian-Najafabadi. "Targeted diphtheria toxin-based therapy: a review article." Frontiers in microbiology 10 (2019): 2340.
- World Health Organization. "Diphtheria vaccine: WHO position paper, August 2017–Recommendations." Vaccine 36.2 (2018): 199-201.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
